How does clozapine differ in efficacy and monitoring from other antipsychotics?

• A. It is a first-line antipsychotic for all schizophrenia cases and requires no special monitoring.
• B. It has no risk of agranulocytosis but requires monthly liver tests.
• C. It is highly effective for treatment-resistant schizophrenia and requires regular ANC monitoring and REMS program due to risks like agranulocytosis.
• D. It is used only for mood stabilization in bipolar disorder and has no use in schizophrenia.

Answer: (C)

Clozapine is set apart because it offers the strongest efficacy for people with treatment-resistant schizophrenia—the subset that doesn’t respond to at least two other antipsychotics. That notable benefit comes with a major safety trade-off: a risk of agranulocytosis, a potentially life-threatening drop in neutrophils. To guard against this, clozapine requires regular monitoring of the white blood cell count and absolute neutrophil count, typically under a risk management (REMS) program that ensures patients and prescribers adhere to monitoring schedules. This combination—the high effectiveness in resistant cases plus mandatory ANC monitoring under REMS—distinguishes clozapine from most other antipsychotics. It’s not a universal first-line choice for all schizophrenia cases, though it can be used for suicidality in schizophrenia; the key distinction remains its powerful efficacy in treatment-resistant illness paired with stringent, ongoing blood monitoring.